top of page

Dr. LI Cho Wing, Bryan

MBBS (HK), MRCP (UK), FHKCP, FHKAM (Med)

Clinical Assistant Professor (HKU)
Honorary Associate Consultant (QMH)

WhatsApp%20Image%202020-12-27%20at%208.5

Biography

Dr. Li graduated from the Faculty of Medicine at the University of Hong Kong in 2004. He completed his basic and higher physician training in the Department of Medicine at Queen Mary Hospital. In 2012, after completing specialist training in both Advanced Internal Medicine and Palliative Medicine, he was admitted as a fellow of internal medicine. Subsequently, Dr. Li worked as a resident specialist and associate consultant in the Palliative Medical Unit at Grantham Hospital. During this time, he also served as an honorary clinical assistant professor in the Medical Ethics and Humanities Unit, where he was involved in teaching and tutoring medical students.

Starting in 2018, Dr. Li underwent specialist training in Medical Oncology at Queen Mary Hospital and was accredited as a specialist in Medical Oncology in 2020. He is currently a Clinical Assistant Professor at the Centre of Cancer Medicine, Department of Medicine, and Department of Obstetrics and Gynecology at the LKS School of Clinical Medicine, University of Hong Kong. Dr. Li focuses on the treatment of genitourinary and gynecological cancers. His research interests include clinical trials and translational research on novel cancer therapeutics. Additionally, he is involved in teaching cancer medicine to undergraduates at the medical school.

Dr. Li is also a member of various professional bodies, including the Medical Oncology Specialty Board of the Hong Kong College of Physicians (HKCP), and the Hong Kong Society of Geriatric Oncology.

李医生于2004年毕业于香港大学医学院。他在玛丽医院的内科完成了基础和高级医生培训。2012年,在完成高级内科和缓和医学的专科培训后,他被接纳为内科专科医生。随后,李医生在葛量洪医院的缓和医学科担任住院专科医生和副顾问医生。在此期间,他还担任医学伦理与人文学科的名誉临床助理教授,参与医学学生的教学和辅导。

从2018年开始,李医生在玛丽医院接受了肿瘤内科专科培训,并于2020年被认证为肿瘤内科专科医生。目前,他是香港大学李嘉诚医学院癌症医学中心、内科以及妇产科的临床助理教授。李医生专注于泌尿生殖系统和妇科癌症的治疗。他的研究兴趣包括新型癌症治疗的临床试验和转化研究。此外,他还参与医学院本科学生的癌症医学教学。

李医生也是多个专业机构的成员,包括香港内科医学院(HKCP)的肿瘤内科专业委员会和香港老年肿瘤学会。

Five Most Representative Publications

1)  Li BC, Chiu J, Shing K, Kwok GG, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT.
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Advances in Therapy. 2021 Jun 1:1-1.

[Citation: - ] [IF: 3.85 (JCR 2020)] 

2) Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J.

Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer

Postgrad Med J. 2021 May 26. doi:10.1136/postgradmedj-2021-140319

[Citation: -] [IF: 2.40 (JCR 2020)] 

3) Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study

Cancers (Basel). 2021 Apr 21;13(9):2002.

[Citation: - ] [IF: 6.64 (JCR 2020)]

4) Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.

Cancers (Basel). 2021 Apr 18;13(8):1949.

[Citation: - ] [IF: 6.64 (JCR 2020)] 

5) Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T.

Drug Profile:  Nivolumab plus Ipilimumab for Patients with Hepatocellular Carcinoma previously treated with Sorafenib

Expert Review of Gastroenterology & Hepatology 2021 Mar 5

[Citation: 2 ] [IF: 3.87 (JCR 2020)] 

Copyright©2023 by Medical Oncology Team, Department of Medicine, The University of Hong Kong. All rights reserved.

bottom of page